Innovation in gene therapy and genome editing raises high expectations for therapeutic breakthroughs. With the increasing maturity of field, products using “gene transfer” technology, such as viral vectors, designer nucleases, incl. CRISPR/Cas, most recent, are frequently tested clinical trials. Before trials launched, anticipated risks benefits transfer technologies must be evaluated to ascert...